Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Danforth Website

David N. Danforth Jr., M.S., M.D.

Selected Publications

1)  Danforth Jr DN.
Disparities in breast cancer outcomes between Caucasian and African American women: a model for describing the relationship of biological and nonbiological factors.
Breast Cancer Res. 15: 208, 2013.
2)  Simone NL, Dan T, Shih J, Smith SL, Sciuto L, Lita E, Lippman ME, Glatstein E, Swain SM, Danforth DN, Camphausen K.
Twenty-five year results of the national cancer institute randomized breast conservation trial.
Breast Cancer Res. Treat. 132: 197-203, 2012.
3)  Danforth DN.
Breast cancer during pregnancy: a comprehensive view.
Cancer J. 16: 68-9, 2010.
4)  Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, Hastings ML, Duelli DM.
Selective release of microRNA species from normal and malignant mammary epithelial cells.
PLoS ONE. 5: e13515, 2010.
5)  Loud JT, Thiébaut AC, Abati AD, Filie AC, Nichols K, Danforth D, Giusti R, Prindiville SA, Greene MH.
Ductal lavage in women from BRCA1/2 families: is there a future for ductal lavage in women at increased genetic risk of breast cancer?.
Cancer Epidemiol. Biomarkers Prev. 18: 1243-51, 2009.
6)  Sportès C, Steinberg SM, Liewehr DJ, Gea-Banacloche J, Danforth DN, Avila DN, Bryant KE, Krumlauf MC, Fowler DH, Pavletic S, Hardy NM, Bishop MR, Gress RE.
Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapy.
Biol. Blood Marrow Transplant. 15: 963-70, 2009.
7)  Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J, Doshi A, Thomasson D, McCarthy N, Koeppen H, Sherman M, Zujewski J, Camphausen K, Chen H, Swain SM.
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.
J. Clin. Oncol. 24: 769-77, 2006.
8)  Danforth DN, Abati A, Prindiville SA, Palmieri D, Simon R, Ried T, Steeg PS.
Combined breast ductal lavage and ductal endoscopy for the evaluation of the high risk breast: A feasability study.
J Surg Oncol. 94: 555-564, 2006.
9)  Eng-Wong J, Reynolds JC, Venzon D, Liewehr D, Gantz S, Danforth D, Liu ET, Chow C, Zujewski J.
Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer.
J Clin Endocrinol Metab. 91: 3941-3946, 2006.
10)  Abati A, Greene MH, Filie A, Loud J, Prindiville S, Danforth D, Giusti RM.
Quantification of the cellular components of breast duct lavage samples.
Diagn. Cytopathol. 34: 78-81, 2006.
11)  Danforth DN.
RE: Safety and feasibility of breast conserving therapy in Indian women: Two decades of experience at tata memorial hospital, by Dinshaw KA, Sarin R, Budrikkar AN, et al.
J Surg Oncol. 94: 89-90, 2006.
12)  Danforth DN, Zhu Y.
Conversion of Fas-resistant to Fas-sensitive MCF-7 breast cancer cells by the synergistic interaction of interferon-gamma and all-trans retinoic acid.
Breast Cancer Res Treat. 94: 81-91, 2005.
13)  Brooks JP, Danforth DN, Albert P, Sciuto LC, Smith SL, Camphausen KA, Poggi MM.
Early ipsilateral breast tumor recurrences after breast conservation affect survival: an analysis of the National Cancer Institute randomized trial.
Int. J. Radiat. Oncol. Biol. Phys. 62: 785-9, 2005.
14)  Neelapu SS, Gause BL, Nikcevich DA, Schuster SJ, Winter J, Gockerman JP, Loughran T, Takeshita K, Inghirami G, McGaughey D, Watson TM, Snow S, Kubovic P, Ferraro M, Jones E, Jaffe ES, Schwartzentruber DJ, Danforth D, Sherry R, Kass E, Van Waes C, Reynolds CW, Kwak LJ.
Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report.
Clin Lymphoma. 6: 61-4, 2005.
15)  Lebowitz PF, Eng-Wong J, Swain SM, Berman A, Merino MJ, Chow CK, Venzon D, Zia F, Danforth D, Liu E, Zujewski J.
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
Clin. Cancer Res. 10: 6764-9, 2004.
16)  Danforth DN.
All-trans retinoic acid acts synergistically with hydroxytamoxifen and transforming-growth factor beta to stimulate apoptosis in MCF-7 breast cancer cells.
J Endocrinol. 183: 395-404, 2004.
17)  Low JA, Berman AW, Steinberg SM, Danforth DN, Lippman ME, Swain SM.
Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy.
J. Clin. Oncol. 22: 4067-74, 2004.
18)  Freedman RJ, Aziz N, Albanes D, Hartman T, Danforth D, Hill S, Sebring N, Reynolds JC, Yanovski JA.
Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer.
J Clin Endocrinol Metab. 85: 2248-53, 2004.
19)  Zujewski JA, Eng-Wong J, O'Shaughnessy J, Venzon D, Chow C, Danforth D, Kohler DR, Cusack G, Riseberg D, Cowan KH.
A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancer.
Breast Cancer Res Treat. 81: 41-51, 2003.
20)  Poggi MM, Danforth DN, Sciuto LC, Smith SL, Steinberg SM, Liewehr DJ, Menard C, Lippman ME, Lichter AS, Altemus RM.
Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast.
Cancer. 98: 697-702, 2003.
21)  Danforth DN, Cowan K, Altemus R, Merino M, Chow C, Berman A, Chaudhry U, Shriver C, Steinberg SM, Zujewski J.
Preoperative FLAC/granulocyte-colony-stimulating factor chemotherapy for stage II breast cancer: A prospective randomized trial.
Ann Surg Oncol. 10: 635-44, 2003.
22)  Lublin M, Bartlett DL, Danforth DN, Kauffman H, Gallin JI, Malech HL, Shawker T, Choyke P, Kleiner DE, Schwartzentruber DJ, Chang R, DeCarlo ES, Holland SM.
Hepatic abscess in patients with chronic granulomatous disease.
Ann Surg. 235: 383-91, 2002.
23)  Danforth DN, Aloj L, Carrasquillo JA, Bacharach SL, Chow C, Zujewski J, Whatley M, Galen B, Merino M, Neumann RD.
The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer.
Breast Cancer Res Treat. 75: 135-46, 2002.
24)  Lublin M, Danforth DN.
Iatrogenic gallbladder perforation: conservative management by percutaneous drainage and cholecystostomy.
Am Surg. 67: 760-3, 2001.
25)  Riddell C, Carson RE, Carrasquillo JA, Libutti SK, Danforth DN, Whatley M, Bacharach SL.
Noise reduction in oncology FDG PET images by iterative reconstruction: a quantitative assessment.
J Nucl Med. 42: 1316-23, 2001.
26)  Danforth DN.
Comments on skin-sparing mastectomy and immediate breast reconstruction: a critical analysis of local recurrence.
Cancer J. 6: 285-6, 2000.
27)  Conley B, O'Shaughnessy J, Prindiville S, Lawrence J, Chow C, Jones E, Merino MJ, Kaiser-Kupfer MI, Caruso RC, Podgor M, Goldspiel B, Venzon D, Danforth D, Wu S, Noone M, Goldstein J, Cowan KH, Zujewski J.
Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer.
J. Clin. Oncol. 18: 275-83, 2000.
Click Here to View Collapsed Bibliography.

This page was last updated on 9/11/2013.